Barlow Carrolee has disclosed important stock transactions in a recent filing, indicating a significant shift in ownership following the merger of Supernus Pharmaceuticals, Inc. with Indivior Pharmaceuticals, Inc. This merger, effective November 2, 2026, marks a notable change in the structure of Supernus, which is now a wholly-owned subsidiary of Indivior.

The filing reveals that Carrolee, a director at Supernus, disposed of 27,045 shares of Supernus common stock as part of the merger agreement. Each share of Supernus was converted into the right to receive 1.5401 shares of Indivior common stock, effectively changing the equity landscape for stakeholders involved.

Background

Barlow Carrolee is a director at Supernus Pharmaceuticals, Inc., which specializes in pharmaceutical preparations. The company is listed under the Central Index Key (CIK) 0001356576. Supernus is headquartered in Rockville, Maryland, and operates within the pharmaceutical industry, focusing on developing and commercializing innovative products for the treatment of central nervous system conditions.

Recent filings from Supernus include a Form 4 and Form 3, both filed on November 4, 2026, indicating ongoing activity surrounding the merger and stock transactions. The company has a history of filings related to stock ownership changes, reflecting its dynamic operational environment.

What the Filing Says

The filing states, "Pursuant to the Agreement and Plan of Merger...each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock." This confirms the conversion of shares as part of the merger process.

Additionally, the filing details that Carrolee disposed of 27,045 shares and acquired 29,989 restricted stock units, which will vest upon certain conditions. The transactions reflect the adjustments made following the merger and the new ownership structure.

Impact

This update may affect various stakeholders, including current shareholders of Supernus and Indivior, as well as potential investors looking at the evolving landscape of the pharmaceutical industry. The merger signifies a consolidation trend that may reshape competitive dynamics, impacting other companies within the pharmaceutical preparations sector.

What's Next

The filing does not specify what happens next regarding further transactions or operational changes following the merger. However, stakeholders will likely monitor how the integration of Supernus into Indivior unfolds in the coming months.